Our PIPELINE
AmMax is leveraging the clinically validated target engagement of its anti-CSF1R antibody to create highly differentiated oncology programs with a well-established safety profile across 6 completed clinical trials in close to 200 patients.
Program
Modality
Indication
First-in-class
Discovery
Preclinical
Phase 1
Phase 2
Market (US/EU)
Program
AMB
066
066
Modality
mAb
Indication
Colorectal cancer with Minimal residual disease (CRC MRD)
First-in-class
Market (US/EU)
>$6bn
Program
AMB
104
104
Modality
ADC
Indication
AML and
solid tumors
First-in-class
Market (US/EU)
>$3bn
Program
AMB
051
051
Modality
mAb
Indication
Tenosynovial giant cell tumor (TGCT)
First-in-class
Market (US/EU)
~$1bn